Connect Biopharma to Participate in the Cantor Fitzgerald Global Healthcare Conference 2024
September 10, 2024 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”), a U.S.-headquartered global clinical-stage...
Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update
September 05, 2024 16:05 ET
|
Connect Biopharma Holdings Limited
Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect’s new management is currently evaluating the...
Connect Biopharma to Participate in the Leerink Partners I&I and Metabolism Therapeutics Forum
July 01, 2024 08:00 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage...
Connect Biopharma Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 12, 2024 18:03 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage...
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
June 12, 2024 16:15 ET
|
Connect Biopharma Holdings Limited
Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the...
Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma
May 22, 2024 16:05 ET
|
Connect Biopharma Holdings Limited
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24Significant improvement in patient-reported asthma...
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
May 07, 2024 06:30 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
April 16, 2024 16:05 ET
|
Connect Biopharma Holdings Limited
Reported two positive readouts for rademikibart, the Company’s lead asset, from the Global Phase 2b trial in moderate-to-severe persistent asthma and from the China pivotal trial in moderate-to-severe...
Connect Biopharma to Participate in H.C. Wainwright 2ⁿᵈ Annual Autoimmune & Inflammatory Disease Virtual Conference
March 19, 2024 08:30 ET
|
Connect Biopharma Holdings Limited
SAN DIEGO and TAICANG, China, March 19, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical...
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
February 12, 2024 16:30 ET
|
Connect Biopharma Holdings Limited
James Huang brings over 30 years of biotech experience as a successful entrepreneur, investor and key opinion leader in the healthcare sector SAN DIEGO, CA and TAICANG, China, Feb. 12, 2024 (GLOBE...